CA2800668A1 - Forms of rifaximin and uses thereof - Google Patents

Forms of rifaximin and uses thereof Download PDF

Info

Publication number
CA2800668A1
CA2800668A1 CA2800668A CA2800668A CA2800668A1 CA 2800668 A1 CA2800668 A1 CA 2800668A1 CA 2800668 A CA2800668 A CA 2800668A CA 2800668 A CA2800668 A CA 2800668A CA 2800668 A1 CA2800668 A1 CA 2800668A1
Authority
CA
Canada
Prior art keywords
rifaximin
cocrystal
theta
piperazine
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2800668A
Other languages
English (en)
French (fr)
Inventor
Yiduo Wu
Stephan D. Parent
Nathan Carl Schultheiss
Melanie Janelle Bevill
Petinka Vlahova
Travis L. Houston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Inc
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of CA2800668A1 publication Critical patent/CA2800668A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2800668A 2010-06-03 2011-06-03 Forms of rifaximin and uses thereof Abandoned CA2800668A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US35128110P 2010-06-03 2010-06-03
US61/351,281 2010-06-03
US35750510P 2010-06-22 2010-06-22
US61/357,505 2010-06-22
US36324110P 2010-07-10 2010-07-10
US61/363,241 2010-07-10
US36351110P 2010-07-12 2010-07-12
US61/363,511 2010-07-12
US36718510P 2010-07-23 2010-07-23
US61/367,185 2010-07-23
US41659310P 2010-11-23 2010-11-23
US61/416,593 2010-11-23
PCT/US2011/039085 WO2011153444A1 (en) 2010-06-03 2011-06-03 New forms of rifaximin and uses thereof

Publications (1)

Publication Number Publication Date
CA2800668A1 true CA2800668A1 (en) 2011-12-08

Family

ID=45067089

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2800668A Abandoned CA2800668A1 (en) 2010-06-03 2011-06-03 Forms of rifaximin and uses thereof

Country Status (18)

Country Link
US (2) US8513275B2 (enExample)
EP (1) EP2575464A4 (enExample)
JP (1) JP2013527246A (enExample)
KR (1) KR20130086338A (enExample)
CN (1) CN103269587A (enExample)
AU (1) AU2011261283B2 (enExample)
BR (1) BR112012030783A2 (enExample)
CA (1) CA2800668A1 (enExample)
CR (1) CR20120620A (enExample)
EA (1) EA022490B1 (enExample)
IL (1) IL222900A (enExample)
MX (1) MX2012013945A (enExample)
NZ (2) NZ710780A (enExample)
PH (1) PH12012502393A1 (enExample)
SG (2) SG10201507035UA (enExample)
TN (1) TN2012000533A1 (enExample)
WO (1) WO2011153444A1 (enExample)
ZA (1) ZA201208770B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
GEP20135898B (en) 2008-02-25 2013-08-12 Salix Pharmaceuticals Ltd Rifaximin forms and usage
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
EP2544660B1 (en) * 2010-03-10 2018-06-13 Lupin Limited Rifaximin ready-to-use suspension
MX350448B (es) * 2011-02-11 2017-09-07 Salix Pharmaceuticals Ltd Formas de rifaximina y usos de las mismas.
EP2705042A1 (en) * 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2773205B1 (en) 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximin for retreating diarrhea-predominant irritable bowel syndrome
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
JP2015528506A (ja) * 2012-09-13 2015-09-28 サリックス ファーマスーティカルズ，インコーポレーテッド 体重減少及び肥満の治療のためのリファキシミンの投与の方法
CA2897758A1 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
EA032705B1 (ru) 2013-04-12 2019-07-31 Альфасигма С.П.А. Способ лечения или предупреждения энтеропатии
ITMI20131307A1 (it) * 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015171493A1 (en) 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
DK3546464T3 (da) 2014-05-12 2020-07-27 Alfasigma Spa Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme
WO2025170483A1 (ru) * 2024-02-07 2025-08-14 Общество с ограниченной ответственностью "БИННОФАРМ ГРУПП" Фармацевтическая композиция, обладающая антибиотической активностью

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US9682043B2 (en) * 2003-12-09 2017-06-20 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
GEP20135898B (en) * 2008-02-25 2013-08-12 Salix Pharmaceuticals Ltd Rifaximin forms and usage

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin

Also Published As

Publication number Publication date
CN103269587A (zh) 2013-08-28
PH12012502393A1 (en) 2013-02-11
SG10201507035UA (en) 2015-10-29
AU2011261283A1 (en) 2012-12-06
TN2012000533A1 (en) 2014-04-01
ZA201208770B (en) 2013-07-31
MX2012013945A (es) 2013-05-06
BR112012030783A2 (pt) 2015-09-29
EA022490B1 (ru) 2016-01-29
US20120108620A1 (en) 2012-05-03
NZ603590A (en) 2015-08-28
IL222900A (en) 2017-11-30
JP2013527246A (ja) 2013-06-27
KR20130086338A (ko) 2013-08-01
EP2575464A1 (en) 2013-04-10
US20130317225A1 (en) 2013-11-28
WO2011153444A1 (en) 2011-12-08
AU2011261283B2 (en) 2015-05-14
IL222900A0 (en) 2012-12-31
SG185490A1 (en) 2012-12-28
US8815888B2 (en) 2014-08-26
EP2575464A4 (en) 2013-10-02
CR20120620A (es) 2014-05-23
US8513275B2 (en) 2013-08-20
NZ710780A (en) 2017-02-24
EA201270808A1 (ru) 2013-04-30

Similar Documents

Publication Publication Date Title
AU2011261283B2 (en) New forms of rifaximin and uses thereof
US9700545B2 (en) Forms of rifaximin and uses thereof
AU2014246594B2 (en) Forms of rifaximin and uses thereof
EP2672970B1 (en) Forms of rifaximin and uses thereof
AU2015203018B2 (en) New forms of rifaximin and uses thereof
HK1191558B (en) Forms of rifaximin and uses thereof
HK1191558A (en) Forms of rifaximin and uses thereof
HK1179608B (en) Forms of rifaximin and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160524

FZDE Discontinued

Effective date: 20210831